Pharma stocks fell in 2018, but innovation soared with 62 new drugs set for $24B in yearly sales: report
admin 28th February 2019 Uncategorised 0There are clear signs of health in the biopharma industry, say analysts at Vantage in their 2018 sector review. But if the animosity toward the industry in Washington yields legislation that limits price hikes, that will put pressure on the industry to increase volume sales with M&A.
More: Pharma stocks fell in 2018, but innovation soared with 62 new drugs set for B in yearly sales: report
Source: fierce